CN115551569A - 用于治疗肺水肿或肺炎的组合物和方法 - Google Patents

用于治疗肺水肿或肺炎的组合物和方法 Download PDF

Info

Publication number
CN115551569A
CN115551569A CN202180038002.8A CN202180038002A CN115551569A CN 115551569 A CN115551569 A CN 115551569A CN 202180038002 A CN202180038002 A CN 202180038002A CN 115551569 A CN115551569 A CN 115551569A
Authority
CN
China
Prior art keywords
dose
lung
serum
hyperoxia
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180038002.8A
Other languages
English (en)
Chinese (zh)
Inventor
D·H·英巴
T·P·里奇
R·J·舒马赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of CN115551569A publication Critical patent/CN115551569A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/125—Adult respiratory distress syndrome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180038002.8A 2020-03-27 2021-03-26 用于治疗肺水肿或肺炎的组合物和方法 Pending CN115551569A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000939P 2020-03-27 2020-03-27
US63/000939 2020-03-27
PCT/US2021/024345 WO2021195488A1 (en) 2020-03-27 2021-03-26 Compositions and methods for treating pulmonary edema or lung inflammation

Publications (1)

Publication Number Publication Date
CN115551569A true CN115551569A (zh) 2022-12-30

Family

ID=77892642

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180038002.8A Pending CN115551569A (zh) 2020-03-27 2021-03-26 用于治疗肺水肿或肺炎的组合物和方法

Country Status (7)

Country Link
US (1) US12569459B2 (https=)
EP (1) EP4126104A4 (https=)
JP (1) JP2023520770A (https=)
CN (1) CN115551569A (https=)
CA (1) CA3177377A1 (https=)
MX (1) MX2022011821A (https=)
WO (1) WO2021195488A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025024778A1 (en) * 2023-07-27 2025-01-30 Regents Of The University Of Minnesota Medical treatment system and methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716877B2 (en) 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
CA2578709C (en) 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
US9220788B2 (en) * 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20090022806A1 (en) 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US8309080B2 (en) 2007-12-06 2012-11-13 Naidu Lp Metallo-protein and tocotrienol (MP-T3) compositions and uses thereof
US8304401B2 (en) 2008-09-02 2012-11-06 Trustees Of Dartmouth College Compositions and methods for decreasing type III deiodinase activity to modulate adiposity and blood glucose levels
WO2010124372A1 (en) * 2009-04-29 2010-11-04 Genomedx Biosciences, Inc. Systems and methods for expression-based classification of thyroid tissue
PT2501413T (pt) 2009-11-18 2019-07-10 Nektar Therapeutics Formas de sal de ácido de conjugados de polímero-fármaco
EP3119768B1 (en) 2014-03-16 2019-07-31 Hadasit Medical Research Services And Development Ltd. 3,4-bromo or -sulfonate substituted 1h-pyrrole-2,5-dione derivatives as type iii deiodinase (dio3) inhibitors for treating depressions and cancer
US9913819B2 (en) 2014-06-12 2018-03-13 Yale University Methods of treating or preventing fibrotic lung diseases
CN107041879A (zh) 2017-04-01 2017-08-15 深圳市润佳通科技有限公司 甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防肺部疾病的药物中的应用
MX2020007971A (es) 2018-01-31 2020-09-09 Univ Minnesota Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
WO2019178023A1 (en) 2018-03-12 2019-09-19 Yale University Methods of Treating or Preventing Acute Respiratory Distress Syndrome

Also Published As

Publication number Publication date
JP2023520770A (ja) 2023-05-19
EP4126104A4 (en) 2024-04-17
US20230147865A1 (en) 2023-05-11
MX2022011821A (es) 2022-10-10
EP4126104A1 (en) 2023-02-08
CA3177377A1 (en) 2021-09-30
US12569459B2 (en) 2026-03-10
WO2021195488A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
US11883528B2 (en) Compositions and methods for treating pulmonary edema or lung inflammation
Downes et al. Mechanisms of antimicrobial-induced nephrotoxicity in children
ES2399279T3 (es) Formulaciones de tobramicina para el tratamiento de infecciones endobronquiales
Alothman et al. Bronchial constriction and inhaled colistin in cystic fibrosis
Ratjen et al. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review
Scott et al. SPX-101 is a novel epithelial sodium channel–targeted therapeutic for cystic fibrosis that restores mucus transport
US6702998B2 (en) Methods and devices for treating lung dysfunction
Vadász et al. Thrombin impairs alveolar fluid clearance by promoting endocytosis of Na+, K+-ATPase
De Luca et al. Pharmacological therapies for pediatric and neonatal ALI/ARDS: an evidence-based review
US10596144B2 (en) Treating or preventing nephrogenic diabetes insipidus
Heching et al. Surfactant for the Treatment of ARDS in a Patient With COVID-19
KR102480800B1 (ko) 엘라스타제 억제 활성을 갖는 베타-헤어핀 펩티드 모방체 및 이의 에어로졸 투여 형태
Chuchalin et al. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements
US20220265775A1 (en) Compositions and methods for treating pulmonary edema or lung inflammation
BR112020020564A2 (pt) Formulações de ciclosporina para uso no tratamento da síndrome de bronquiolite obliterante (bos)
US12569459B2 (en) Compositions and methods for treating pulmonary edema or lung inflammation
HK40087339A (zh) 用於治疗肺水肿或肺炎的组合物和方法
JP2012506860A5 (https=)
RU2737799C1 (ru) Ингаляционный гексапептид для лечения респираторных заболеваний, связанных с интерлейкином-6
HK40046684A (en) Compositions and methods for treating pulmonary edema or lung inflammation
Dupont et al. A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace™) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
Narasimhan et al. New and investigational treatments in cystic fibrosis
Griffith et al. Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK-PD implications
Baradia et al. Inhalation therapy to treat pulmonary arterial hypertension
Kappeler et al. Liposomal Cyclosporine A for Inhalation (L-CsA-i) to Treat Bronchiolitis Obliterans Syndrome: Novel Formulation and Drug-Specific Delivery System Improve Tolerability

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40087339

Country of ref document: HK